Login / Signup

Flattening the Risk: Pre-Exposure Prophylaxis for COVID-19.

Raphael B StrickerMelissa C Fesler
Published in: Infection and drug resistance (2020)
To date, more than 35 million people worldwide have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent of coronavirus disease 2019 (COVID-19), and more than one million have died in the COVID-19 pandemic. International economies are stalled and social isolation based on palpable fear of death remains the order of the day. The United States and other countries are moving toward resuming work activities and social interaction to boost economic recovery. While this makes financial sense, from a medical perspective our population has already suffered and will continue to suffer severe losses in the absence of a viable aggressive prophylaxis strategy for SARS-CoV-2. Herein, we present a plan to address this problem.
Keyphrases
  • respiratory syndrome coronavirus
  • sars cov
  • coronavirus disease
  • healthcare
  • mental health
  • drug induced